The Advanced Wound Management
division of Smith & Nephew plc (LSE: SN; NYSE:SNN) announced today
the launch of a new product to expand the ACTICOAT* family. ACTICOAT
Flex has been designed to support physicians dealing with injuries at
high risk of infection. The dressings utilize the tried and trusted
Silcryst(R) nano-crystalline silver technology and are highly
conformable - ideal for awkward anatomical areas such as face and
hands to improve patient comfort during wear.
Initially the product will be available in Canada with the USA and EU
markets launching early in 2009. The ACTICOAT franchise has enjoyed
seven years of continuing success in the silver dressing category,
since its invention and introduction in Canada, through strong,
reliable clinical and economic performance. The latest product to
join the family continues this tradition by further enhancing the
patient benefits delivered through this valuable, proprietary
technology.
"This new product represents an exciting and significant development
for the ACTICOAT brand. It has been developed by listening to
clinicians and understanding their needs for fighting wound
infection. The development was possible due to the ongoing strength of
our partnership with Nucryst Pharmaceuticals and demonstrates the
capability of the unique Silcryst silver technology to meet the
stringent and rapidly advancing needs of our customers", said Roger
Teasdale, Senior Vice President of the Advance Woundcare Strategic
Business Unit.
"We are very pleased with ACTICOAT Flex, it represents our commitment
in supplying the correct tools for healthcare professionals, to help
reduce the risk of Health Care Acquired Infection" commented Joe
Woody, President of Smith & Nephew Wound Management. "This product
launch is a key to our focus on Infection Management, one the three
focused elements of the Wound Management Global Business Unit strategy
along with Exudate Management and Negative Pressure Wound Therapy.
* Trademark of Smith & Nephew
(R) Trademark of Nucryst Pharmaceuticals
About Smith & Nephew
Smith & Nephew is a global medical technology business, specializing
in Orthopedic Reconstruction, Orthopedic Trauma and Clinical
Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is
a global leader in arthroscopy and advanced wound management and is
one of the leading global orthopedics companies. Smith & Nephew is
dedicated to helping improve people's lives. The Company prides
itself on the strength of its relationships with its surgeons and
professional healthcare customers, with whom its name is synonymous
with high standards of performance, innovation and trust. The
Company operates in 32 countries around the world. Annual sales in
2007 were nearly USD3.4billion. global.smith-nephew
About NUCRYST Pharmaceuticals
NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops,
manufactures and commercializes medical products that fight infection
and inflammation using SILCRYST(TM), its patented atomically
disordered nanocrystalline silver technology. NUCRYST licensed
world-wide rights for SILCRYST(TM) wound care coating products to
Smith & Nephew plc, which markets these products in over 30 countries
under their ACTICOAT(TM) trademark. NUCRYST is also developing
pharmaceutical products to address medical conditions that are
characterized by pain, infection and inflammation. The Company has
developed its proprietary nanocrystalline silver in a powder form,
referred to as NPI 32101 for use in medical devices and as an active
pharmaceutical ingredient. nucryst
Forward-Looking Statements
This press release contains certain "forward-looking statements"
within the meaning of the US Private Securities Litigation Reform Act
of 1995. In particular, statements regarding expected revenue growth
and trading margins are forward-looking statements as are discussions
of our product pipeline. These statements, as well as the phrases
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions,
are generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors (including, but not limited
to, the harmonization of sales practices, the outcome of litigation,
claims and regulatory approvals) that could cause the actual results,
performance or achievements of Smith & Nephew, or industry results,
to differ materially from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Please refer to the documents that Smith & Nephew has filed with the
U.S. Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20F, for a discussion of certain of
these factors.
All forward-looking statements in this press release are based on
information available to Smith & Nephew as of the date hereof. All
written or oral forward-looking statements attributable to Smith &
Nephew or any person acting on behalf of Smith & Nephew are expressly
qualified in their entirety by the foregoing. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement contained herein to reflect any change in Smith & Nephew's
expectation with regard thereto or any change in events, conditions
or circumstances on which any such statement is based.
NUCRYST Pharmaceuticals